Regulus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Regulus Therapeutics
RGLS Stock  USD 1.28  0.01  0.79%   
Regulus Therapeutics financial statements provide useful quarterly and yearly information to potential Regulus Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regulus Therapeutics financial statements helps investors assess Regulus Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regulus Therapeutics' valuation are summarized below:
Gross Profit
-22.6 M
Market Capitalization
83.8 M
Enterprise Value Revenue
0.6573
Revenue
5 M
Earnings Share
(1.02)
There are over one hundred nineteen available trending fundamental ratios for Regulus Therapeutics, which can be analyzed over time and compared to other ratios. All traders should check out Regulus Therapeutics' recent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 26.5 M in 2025. Enterprise Value is likely to drop to about 3.2 M in 2025

Regulus Therapeutics Total Revenue

0.0

Check Regulus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regulus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 194.1 K, Interest Expense of 1.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 4.03, Dividend Yield of 0.0 or PTB Ratio of 1.63. Regulus financial statements analysis is a perfect complement when working with Regulus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Regulus Therapeutics Correlation against competitors.
For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

Regulus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets26.3 M27.7 M70.5 M
Slightly volatile
Total Current Liabilities15.5 M9.8 M13.9 M
Very volatile
Other Liabilities1 M1.1 M7.2 M
Slightly volatile
Accounts Payable174.4 K183.6 K1.5 M
Slightly volatile
Cash35.1 M21.4 M42 M
Pretty Stable
Common Stock Shares Outstanding22.9 M21.8 M6 M
Slightly volatile
Other Current Assets1.2 M1.3 M3.3 M
Pretty Stable
Total Liabilities8.2 M8.6 M29.5 M
Slightly volatile
Intangible Assets28.2 K29.7 K584.7 K
Slightly volatile
Property Plant Equipment3.6 M2.3 M4.2 M
Pretty Stable
Short and Long Term Debt Total2 M2.2 M11.7 M
Slightly volatile
Property Plant And Equipment Net3.6 M2.3 M4.2 M
Pretty Stable
Non Current Assets Total4.4 M2.3 M5.2 M
Slightly volatile
Non Currrent Assets Other3.6 M3.5 M1.2 M
Slightly volatile
Cash And Short Term Investments20.3 M21.4 M59 M
Slightly volatile
Liabilities And Stockholders Equity26.3 M27.7 M69.4 M
Slightly volatile
Non Current Liabilities Total902 K949.5 K18.7 M
Slightly volatile
Other Stockholder Equity377.9 M614.5 M341.2 M
Slightly volatile
Property Plant And Equipment Gross6 M7.8 M5.5 M
Slightly volatile
Total Current Assets24.1 M25.4 M64.4 M
Slightly volatile
Short Term Debt1.1 M1.2 M6.2 M
Pretty Stable
Common Stock Total Equity53 K77 K52.3 K
Slightly volatile
Long Term Debt Total47.9 K50.4 K7.4 M
Slightly volatile
Capital Surpluse356.5 M521 M336.9 M
Slightly volatile
Deferred Long Term Liabilities6.7 M9 M10.1 M
Slightly volatile
Common Stock21.9 K23 K45.9 K
Very volatile
Short and Long Term Debt1.1 M1.2 M14.1 M
Slightly volatile
Net Invested Capital28.7 M20.3 M42.8 M
Slightly volatile
Capital Stock55.2 K28.8 K28.6 K
Slightly volatile

Regulus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization194.1 K204.3 K1 M
Slightly volatile
Interest Expense1.1 M694.6 K950.6 K
Slightly volatile
Other Operating Expenses32.6 M28 M39.4 M
Pretty Stable
Research Development24.1 M18.9 M29 M
Pretty Stable
Cost Of Revenue22.8 M19 M27.5 M
Slightly volatile
Total Operating Expenses8.5 M9 M35.4 M
Slightly volatile
Selling General Administrative9.4 M9 M10.6 M
Pretty Stable
Interest Income2 M1.9 M907 K
Slightly volatile
Reconciled Depreciation157.3 K165.6 K1.6 M
Slightly volatile
Selling And Marketing Expenses65.6 K73.8 K80.5 K
Slightly volatile

Regulus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M2.5 M4.6 M
Very volatile
Begin Period Cash Flow27.6 M27.9 M25.4 M
Slightly volatile
Depreciation194.1 K204.3 K1 M
Slightly volatile
Capital Expenditures611.5 K551.7 K741.6 K
Slightly volatile
End Period Cash Flow28.1 M27.4 M25.9 M
Pretty Stable
Change To Netincome1.8 M1.9 M5.6 M
Pretty Stable
Sale Purchase Of Stock27.7 M17.2 M34.1 M
Slightly volatile
Issuance Of Capital Stock18 M13.7 M10.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.034.2591.3015
Very volatile
Days Sales Outstanding15.6916.51181
Very volatile
Stock Based Compensation To Revenue0.220.2412.2759
Very volatile
Capex To Depreciation3.263.111.4185
Pretty Stable
Payables Turnover97.9893.3225.183
Slightly volatile
Sales General And Administrative To Revenue0.750.7927.5605
Very volatile
Research And Ddevelopement To Revenue1.311.3880.6214
Very volatile
Capex To Revenue9.0E-40.0010.3933
Very volatile
Cash Per Share1.371.442.9 K
Slightly volatile
Days Payables Outstanding3.013.174.3 K
Very volatile
Intangibles To Total Assets0.00120.00120.0079
Slightly volatile
Current Ratio3.623.816.7355
Slightly volatile
Receivables Turnover42.2622.8873.4548
Slightly volatile
Graham Number6.897.264.4 K
Slightly volatile
Capex Per Share0.03530.037290.1067
Slightly volatile
Revenue Per Share3.133.29676
Slightly volatile
Interest Debt Per Share0.170.18689
Slightly volatile
Debt To Assets0.08490.08930.1856
Pretty Stable
Operating Cycle44.4146.7512.4 K
Pretty Stable
Days Of Payables Outstanding3.013.174.3 K
Very volatile
Ebt Per Ebit1.181.111.0815
Pretty Stable
Quick Ratio3.233.46.6455
Slightly volatile
Net Income Per E B T1.11.151.0152
Slightly volatile
Cash Ratio5.313.214.762
Pretty Stable
Days Of Sales Outstanding15.6916.51181
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.810.920.9943
Slightly volatile
Fixed Asset Turnover20.0319.089.5867
Slightly volatile
Debt Ratio0.08490.08930.1856
Pretty Stable
Price Sales Ratio4.034.2591.3015
Very volatile
Asset Turnover0.320.310.1757
Slightly volatile

Regulus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap26.5 M27.9 M262.4 M
Slightly volatile

Regulus Fundamental Market Drivers

Cash And Short Term Investments23.8 M

Regulus Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Regulus Therapeutics Financial Statements

Regulus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Regulus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Regulus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Regulus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-530.1 K-503.6 K
Cost Of Revenue19 M22.8 M
Stock Based Compensation To Revenue 0.24  0.22 
Sales General And Administrative To Revenue 0.79  0.75 
Research And Ddevelopement To Revenue 1.38  1.31 
Revenue Per Share 3.29  3.13 
Ebit Per Revenue(1.63)(1.71)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY